HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Health-related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non-interventional study (NIS).

AbstractINTRODUCTION:
Real-world data (RWD) on health-related outcomes in persons with haemophilia A (PwHA) provide insights into patient needs and can guide clinical study design. A global, prospective, non-interventional study (NIS; NCT02476942) collected detailed RWD on bleeding outcomes, health-related quality of life (HRQoL) and health status in PwHA treated per local routine clinical practice.
AIM:
To report HRQoL and health status in the adult/adolescent PwHA with inhibitors cohort in the NIS.
METHODS:
This cohort enrolled PwHA aged ≥12 years with high-titre factor VIII inhibitor history. Participants remained on their usual treatment (no protocol-specified interventions). Health-related outcomes: Haemophilia Quality of Life Questionnaire for Adults (Haem-A-QoL), Haemophilia-specific Quality of Life Questionnaire for Children Short Form (Haemo-QoL SF), EuroQol 5-Dimensions 5-Levels (EQ-5D-5L) index utility score (IUS) and visual analogue scale (EQ-VAS).
RESULTS:
One hundred three participants were enrolled on episodic (n = 75) or prophylactic treatment (n = 28); median (range) age, 31 (12-75) years; median (range) observation time, 26 (4-70) weeks. Haem-A-QoL scores indicated impairments in HRQoL aspects; comparable between episodic/prophylactic regimens and relatively consistent over time. Haemo-QoL SF scores with both regimens varied over time, and appeared poorer with episodic than prophylactic treatment. IUS and EQ-VAS were comparable between regimens, stable over time and lower on bleeding days. Mean proportions of missed work and school days were 16% and 23%, respectively; mean (standard deviation) number of days hospitalized was 3.2 (8.8) (comparable between groups).
CONCLUSIONS:
These RWD demonstrate that PwHA with inhibitors have impaired HRQoL, despite standard treatment, and that more effective treatment options are needed.
AuthorsJohnny Mahlangu, Johannes Oldenburg, Michael U Callaghan, Midori Shima, Maria Elisa Mancuso, Peter Trask, Michael Recht, Claudia Garcia, Renchi Yang, Michaela Lehle, Harrison Macharia, Elina Asikanius, Gallia G Levy, Rebecca Kruse-Jarres, Sylvia von Mackensen
JournalHaemophilia : the official journal of the World Federation of Hemophilia (Haemophilia) Vol. 25 Issue 3 Pg. 382-391 (May 2019) ISSN: 1365-2516 [Electronic] England
PMID31016855 (Publication Type: Journal Article, Multicenter Study)
Copyright© 2019 The Authors. Haemophilia Published by John Wiley & Sons Ltd.
Topics
  • Absenteeism
  • Adolescent
  • Adult
  • Aged
  • Child
  • Female
  • Health Status
  • Hemophilia A (complications, epidemiology)
  • Hemorrhage (complications)
  • Hospitalization (statistics & numerical data)
  • Humans
  • Male
  • Middle Aged
  • Prospective Studies
  • Quality of Life
  • Schools (statistics & numerical data)
  • Surveys and Questionnaires
  • Work (statistics & numerical data)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: